Financial Results for the quarter and year ended March 31, 2025. Further please note the below mentioned details of borrowing as system was not allowing us to take decimal: 1. Outstanding ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 3.0 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Globalspace Technologies reported audited results for Q4 and FY25 on May 23, 2025. Standalone revenue from operations came in at Rs 517.62 lakhs for Q4 and Rs 2,932.48 lakhs for the full year (vs Rs 2,904.80 lakhs last year), a marginal ~1% rise. Consolidated revenue grew much sharper at Rs 4,304.58 lakhs (vs Rs 2,904.80 lakhs), up about 48%, helped by subsidiary Innopharm Healthcare. The company reported a standalone net loss of Rs 183.71 lakhs for FY25 (vs Rs 353.11 lakhs loss last year) and a consolidated net loss of Rs 199.92 lakhs, with losses partly driven by exceptional items of Rs 275.65 lakhs. Operating margin shrank from 17% to 12% and standalone operating cash flow was negative at Rs -202.50 lakhs. The board also re-appointed Maheshwari Maheshwari & Co. as internal auditor for FY26 and granted 75,000 ESOP options.
Loss-making year with margin compression despite consolidated revenue growth from subsidiaries, though the net loss narrowed versus last year. The pending Rs 1,144.33 lakhs equity commitment into Miljon Medi App Pvt Ltd remains a watch point for shareholders.